Updates are available Correction dated 2021-10-16
Click to view Correction: https://doi.org/10.1007/s10620-021-07275-w
-
Authors
Vijayvargiya, Priya
Gonzalez Izundegui, Daniel
Calderon, Gerardo
Tawfic, Sarah
Batbold, Sarah
Saifuddin, Hiba
Duggan, Patrick
Melo, Valeria
Thomas, Taylor
Heeney, Megan
Beyde, Adrian
Miller, James Jr.
Valles, Kenneth
Oyemade, Kafayat
Brant, Joseph F.
Atieh, Jessica
Donato, Leslie J.
Camilleri, Michael https://orcid.org/0000-0001-6472-7514
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01-DK115950)
- License Information
-
More Information
Article History
Received: 13 November 2020
Accepted: 8 April 2021
First Online: 22 April 2021
Change Date: 16 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10620-021-07275-w
Declarations
:
: Michael Camilleri has received research grants from Allergan and Novartis to study treatments for bile acid diarrhea (specifically eluxadoline and tropifexor, respectively). The other authors have no conflicts of interest.
: This retrospective review study was approved by the Mayo Clinic Institutional Review Board (IRB #17–009774) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The records of all patients between January 1, 2015 and December 17, 2019 were evaluated.
: The study was based on the retrospective review of the medical records of patients who had approved use of their medical records for research purposes.
